Home › Companies › BioCryst Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BioCryst Pharmaceuticals, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2026: 6 items on BioCryst Pharmaceuticals, Inc.’s Form 8-K, filed June 12, 2026: 3 elected · 3 approved.
Significant dissent: 1 say-on-pay vote (68.9% support); 1 equity or compensation plan (34.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BioCryst Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are BioCryst Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Theresa M. Heggie | 176,939,696 | -- | -- | 6,915,770 | -- | 96% | Elected | — |
| Elect Director: Amy E. McKee, M.D. | 178,820,838 | -- | -- | 5,034,628 | -- | 97% | Elected | — |
| Elect Director: Jon P. Stonehouse | 173,944,412 | -- | -- | 9,911,054 | -- | 95% | Elected | — |
| The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026 | 210,304,554 | 7,192,262 | 396,293 | -- | -- | 97% | Approved | — |
| The proposed non-binding, advisory resolution regarding executive compensation | 126,098,528 | 56,797,571 | 959,367 | -- | 34,037,643 | 69% | Approved | — |
| The Incentive Plan Proposal | 119,765,948 | 63,275,217 | 814,301 | -- | 34,037,643 | 65% | Approved | — |
Source: BioCryst Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
309 asset managers disclosed a vote on at least one BioCryst Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Amy E. Mckee, M.D.
BioCryst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Amy E. McKee, M.D.”): 178,820,838 for, 5,034,628 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 62,615,949 for, 230,300 withheld, 14 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,295,716 | 0 | 14 | 0 | For |
| BlackRock | 9,609,520 | 0 | 0 | 0 | For |
| State Street | 7,455,833 | 0 | 0 | 0 | For |
| Fidelity | 5,725,028 | 0 | 0 | 0 | For |
| TIAA | 3,595,530 | 0 | 0 | 0 | For |
| Charles Schwab | 2,352,390 | 0 | 0 | 0 | For |
| Aberdeen | 1,960,732 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 1,568,440 | 0 | 0 | 0 | For |
| First Trust | 1,012,177 | 0 | 0 | 0 | For |
| Invesco | 750,281 | 0 | 0 | 0 | For |
| AMG FUNDS | 698,156 | 0 | 0 | 0 | For |
| Equitable | 322,652 | 0 | 0 | 183,774 | Mixed |
| Principal Exchange-Traded Funds | 420,966 | 0 | 0 | 0 | For |
| Dimensional | 388,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 333,308 | 0 | 0 | 0 | For |
| Voya | 322,895 | 0 | 0 | 0 | For |
| Lincoln Financial | 257,810 | 0 | 0 | 0 | For |
| Virtus | 256,833 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 234,472 | 0 | 0 | 0 | For |
| JPMorgan | 215,976 | 0 | 0 | 0 | For |
| Federated Hermes | 215,610 | 0 | 0 | 0 | For |
| Northern Trust | 202,239 | 0 | 0 | 0 | For |
| ProShares | 199,540 | 0 | 0 | 0 | For |
| Putnam | 181,722 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 175,458 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jon P. Stonehouse”): 173,944,412 for, 9,911,054 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 62,602,380 for, 243,853 withheld, 29 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,273,871 | 0 | 29 | 21,829 | For |
| BlackRock | 9,609,520 | 0 | 0 | 0 | For |
| State Street | 7,446,115 | 0 | 0 | 9,718 | For |
| Fidelity | 5,725,028 | 0 | 0 | 0 | For |
| TIAA | 3,595,530 | 0 | 0 | 0 | For |
| Charles Schwab | 2,352,390 | 0 | 0 | 0 | For |
| Aberdeen | 1,960,732 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 1,568,440 | 0 | 0 | 0 | For |
| First Trust | 1,012,177 | 0 | 0 | 0 | For |
| Invesco | 750,281 | 0 | 0 | 0 | For |
| AMG FUNDS | 698,156 | 0 | 0 | 0 | For |
| Equitable | 322,652 | 0 | 0 | 183,774 | Mixed |
| Principal Exchange-Traded Funds | 420,966 | 0 | 0 | 0 | For |
| Dimensional | 388,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 333,308 | 0 | 0 | 0 | For |
| Voya | 322,895 | 0 | 0 | 0 | For |
| Lincoln Financial | 257,810 | 0 | 0 | 0 | For |
| Virtus | 256,833 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 234,472 | 0 | 0 | 0 | For |
| JPMorgan | 215,976 | 0 | 0 | 0 | For |
| Federated Hermes | 215,610 | 0 | 0 | 0 | For |
| Northern Trust | 202,239 | 0 | 0 | 0 | For |
| ProShares | 199,540 | 0 | 0 | 0 | For |
| Putnam | 181,722 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 175,458 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Theresa M. Heggie
BioCryst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Theresa M. Heggie”): 176,939,696 for, 6,915,770 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 62,370,479 for, 475,764 withheld, 20 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,295,710 | 0 | 20 | 0 | For |
| BlackRock | 9,609,520 | 0 | 0 | 0 | For |
| State Street | 7,455,833 | 0 | 0 | 0 | For |
| Fidelity | 5,725,028 | 0 | 0 | 0 | For |
| TIAA | 3,595,530 | 0 | 0 | 0 | For |
| Charles Schwab | 2,352,390 | 0 | 0 | 0 | For |
| Aberdeen | 1,960,732 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 1,568,440 | 0 | 0 | 0 | For |
| First Trust | 1,012,177 | 0 | 0 | 0 | For |
| Invesco | 750,281 | 0 | 0 | 0 | For |
| AMG FUNDS | 698,156 | 0 | 0 | 0 | For |
| Equitable | 322,652 | 0 | 0 | 183,774 | Mixed |
| Principal Exchange-Traded Funds | 420,966 | 0 | 0 | 0 | For |
| Dimensional | 388,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 333,308 | 0 | 0 | 0 | For |
| Voya | 322,895 | 0 | 0 | 0 | For |
| Lincoln Financial | 228,322 | 0 | 0 | 29,488 | Mixed |
| Virtus | 256,833 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 234,472 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 215,976 | Withhold |
| Federated Hermes | 215,610 | 0 | 0 | 0 | For |
| Northern Trust | 202,239 | 0 | 0 | 0 | For |
| ProShares | 199,540 | 0 | 0 | 0 | For |
| Putnam | 181,722 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 175,458 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
65% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE STOCK INCENTIVE PLAN.
BioCryst Pharmaceuticals, Inc.’s own tally for this item (“The Incentive Plan Proposal was approved by the following votes:”): 119,765,948 for, 63,275,217 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Incentive Plan Proposal was approved by the following votes:”
Support: 65% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 43,014,934 for, 19,732,291 against, 34,298 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,273,717 | 22,011 | 1 | 0 | For |
| BlackRock | 9,609,520 | 0 | 0 | 0 | For |
| State Street | 5,374 | 7,450,459 | 0 | 0 | Against |
| Fidelity | 5,144,361 | 580,667 | 0 | 0 | Mixed |
| TIAA | 0 | 3,595,530 | 0 | 0 | Against |
| Charles Schwab | 2,352,390 | 0 | 0 | 0 | For |
| Aberdeen | 1,960,732 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 0 | 1,568,440 | 0 | 0 | Against |
| First Trust | 0 | 1,012,177 | 0 | 0 | Against |
| Invesco | 0 | 750,281 | 0 | 0 | Against |
| AMG FUNDS | 0 | 698,156 | 0 | 0 | Against |
| Equitable | 322,652 | 183,774 | 2,360 | 0 | Mixed |
| Principal Exchange-Traded Funds | 0 | 420,966 | 0 | 0 | Against |
| Dimensional | 0 | 388,034 | 0 | 0 | Against |
| Goldman Sachs | 0 | 333,308 | 0 | 0 | Against |
| Voya | 0 | 322,895 | 0 | 0 | Against |
| Lincoln Financial | 29,488 | 228,322 | 0 | 0 | Mixed |
| Virtus | 0 | 256,833 | 0 | 0 | Against |
| JPMorgan | 215,976 | 0 | 0 | 0 | For |
| Federated Hermes | 215,610 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 202,239 | 0 | 0 | Against |
| ProShares | 0 | 199,540 | 0 | 0 | Against |
| Putnam | 0 | 181,722 | 0 | 0 | Against |
| Bridge Builder Trust | 143,066 | 32,392 | 0 | 0 | Mixed |
| ALGER FUNDS | 0 | 155,560 | 0 | 0 | Against |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
69% Approved · of votes cast
Prior year: 95.8% for (June 12, 2025 meeting) ▼ 26.8 pts
Description as filed by funds: To hold a non-binding, advisory vote regarding executive compensation.
BioCryst Pharmaceuticals, Inc.’s own tally for this item (“The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”): 126,098,528 for, 56,797,571 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of BioCryst Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “COMPENSATION” (2 managers, 320 for); “Say on Pay” (2 managers, 1,237 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,295,566 | 163 | 2 | 0 | For |
| BlackRock | 1,005,927 | 8,603,593 | 0 | 0 | Mixed |
| State Street | 7,447,219 | 8,614 | 0 | 0 | For |
| Fidelity | 774,555 | 4,950,473 | 0 | 0 | Mixed |
| TIAA | 3,595,530 | 0 | 0 | 0 | For |
| Charles Schwab | 2,352,390 | 0 | 0 | 0 | For |
| Aberdeen | 1,960,732 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 1,568,440 | 0 | 0 | 0 | For |
| First Trust | 0 | 1,012,177 | 0 | 0 | Against |
| Invesco | 0 | 750,281 | 0 | 0 | Against |
| AMG FUNDS | 698,156 | 0 | 0 | 0 | For |
| Equitable | 2,360 | 506,426 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 0 | 420,966 | 0 | 0 | Against |
| Dimensional | 0 | 388,034 | 0 | 0 | Against |
| Goldman Sachs | 333,308 | 0 | 0 | 0 | For |
| Voya | 322,895 | 0 | 0 | 0 | For |
| Lincoln Financial | 178,874 | 78,936 | 0 | 0 | Mixed |
| Virtus | 0 | 256,833 | 0 | 0 | Against |
| JPMorgan | 215,976 | 0 | 0 | 0 | For |
| Federated Hermes | 215,610 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 202,239 | 0 | 0 | Against |
| ProShares | 0 | 199,540 | 0 | 0 | Against |
| Putnam | 0 | 181,722 | 0 | 0 | Against |
| Bridge Builder Trust | 93,500 | 81,958 | 0 | 0 | Mixed |
| ALGER FUNDS | 0 | 155,560 | 0 | 0 | Against |
Fund voting reports, all 75 managers: 43,742,102 for, 18,998,913 against, 27,219 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 15,186,732 | 0 | 0 | 0 | For |
| State Street | 11,989,926 | 98,759 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 10,862,630 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 9,401,407 | 0 | 0 | 0 | For |
| BlackRock | 1,737,406 | 5,462,432 | 0 | 0 | Mixed |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 5,677,962 | 0 | 0 | Against |
| Aberdeen | 5,040,670 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 0 | 4,158,394 | 0 | 0 | Against |
| Frazier Life Sciences Management, L.P. | 4,009,240 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 3,950,268 | 0 | 0 | 0 | For |
| Nuveen | 3,693,642 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 64,980 | 0 | 0 | 0 | For |
| Charles Schwab | 2,353,492 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 2,286,841 | 0 | 0 | Against |
| Vanguard | 2,015,965 | 9,959 | 0 | 0 | For |
| Fisher Asset Management, LLC | 0 | 1,920,526 | 0 | 0 | Against |
| 1919 Investment Counsel, LLC | 0 | 1,804,977 | 0 | 0 | Against |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,784,751 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 1,481,788 | 0 | 0 | Against |
| JUPITER ASSET MANAGEMENT LTD | 0 | 1,464,307 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 1,425,200 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 1,416,201 | 0 | 0 | Against |
| Legal & General Investment Management Ltd | 1,367,922 | 0 | 0 | 0 | For |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 0 | 1,257,871 | 0 | 0 | Against |
| Invesco | 0 | 1,123,455 | 0 | 0 | Against |
Institutional-manager reports, all 249 managers: 81,849,557 for, 36,447,265 against, 1,000 abstained, 7,230 not voted, 2,550,474 mixed. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 97.8% for (June 12, 2025 meeting) ▼ 1.2 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 2026.
BioCryst Pharmaceuticals, Inc.’s own tally for this item (“The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026 was approved by the following votes:”): 210,304,554 for, 7,192,262 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026 was approved by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 62,648,023 for, 173,381 against, 27,217 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,283,017 | 12,711 | 0 | 0 | For |
| BlackRock | 9,609,520 | 0 | 0 | 0 | For |
| State Street | 7,452,888 | 2,945 | 0 | 0 | For |
| Fidelity | 5,725,028 | 0 | 0 | 0 | For |
| TIAA | 3,595,530 | 0 | 0 | 0 | For |
| Charles Schwab | 2,352,390 | 0 | 0 | 0 | For |
| Aberdeen | 1,960,732 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 1,568,440 | 0 | 0 | 0 | For |
| First Trust | 1,012,177 | 0 | 0 | 0 | For |
| Invesco | 750,281 | 0 | 0 | 0 | For |
| AMG FUNDS | 698,156 | 0 | 0 | 0 | For |
| Equitable | 508,786 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 420,966 | 0 | 0 | 0 | For |
| Dimensional | 388,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 333,308 | 0 | 0 | 0 | For |
| Voya | 322,895 | 0 | 0 | 0 | For |
| Lincoln Financial | 257,810 | 0 | 0 | 0 | For |
| Virtus | 256,833 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 234,472 | 0 | 0 | 0 | For |
| JPMorgan | 215,976 | 0 | 0 | 0 | For |
| Federated Hermes | 215,610 | 0 | 0 | 0 | For |
| Northern Trust | 202,239 | 0 | 0 | 0 | For |
| ProShares | 199,540 | 0 | 0 | 0 | For |
| Putnam | 181,722 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 175,458 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 254,162,660 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.77% |
| 2 | BlackRock | 3.78% |
| 3 | State Street | 2.93% |
| 4 | Fidelity | 2.25% |
| 5 | TIAA | 1.41% |
| 6 | Charles Schwab | 0.93% |
| 7 | Aberdeen | 0.77% |
| 8 | Pacer Funds Trust | 0.62% |
| 9 | First Trust | 0.40% |
| 10 | Invesco | 0.30% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 5.98% |
| 2 | State Street | 4.76% |
| 3 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4.27% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 3.70% |
| 5 | BlackRock | 2.83% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.23% |
| 7 | Aberdeen | 1.98% |
| 8 | Vestal Point Capital, LP | 1.64% |
| 9 | Frazier Life Sciences Management, L.P. | 1.58% |
| 10 | PERCEPTIVE ADVISORS LLC | 1.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| The Vanguard Group | 20,730,939 | 8.16% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
| BlackRock, Inc. | 17,483,490 | 6.88% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
| RA Capital Management, L.P. | 15,827,186 | 6.23% | Schedule 13G, filed August 14, 2026 |
| RA Capital Healthcare Fund, L.P. | 15,302,186 | 6.02% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
| STATE STREET CORPORATION | 15,191,098 | 5.98% | Schedule 13G, filed August 7, 2026 |
| Deerfield Mgmt, L.P. | 14,341,000 | 5.64% | Schedule 13G, filed February 12, 2026 |
| Deerfield Partners, L.P. | 14,341,000 | 5.64% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
| Vanguard Capital Management | 12,961,172 | 5.10% | Schedule 13G, filed April 29, 2026 |
| Jon P. Stonehouse | 5,516,462 | 2.17% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
| Alane P. Barnes | 1,295,128 | 0.51% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
Percentages above are of 254,162,660 shares outstanding, as reported by BioCryst Pharmaceuticals, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BioCryst Pharmaceuticals, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 309 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,809 separate fund positions. On the most widely held item on that ballot — To hold a non-binding, advisory vote regarding executive compensation. — BioCryst Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 69% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BioCryst Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BioCryst Pharmaceuticals, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BioCryst Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “BioCryst Pharmaceuticals (BCRX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biocryst-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.